Service > Psoriasis Awareness
Bookmark and Share

 

Minimize

 

The Psoriasis Awareness Group is a branch of DIGA dedicated to providing support for psoriasis patients, advocating for funding of psoriasis research, and participating in various events to promote awareness of this condition and the nearly 7.5 million Americans who suffer from it. We also work closely with the National Psoriasis Foundation (www.psoriasis.org) to reach these goals. As students, we can be a great resource for the NPF, which relies heavily on support from its volunteers. For more information on how to get involved with this committee and local events in your area, to share examples of how your local DIG Chapter has worked to promote psoriasis advocacy, or to pitch an idea for a future program or event, please contact John Zade at jzade14@gmail.com


TO FIND OUT MORE ABOUT PSORIASIS CHECK OUT THE NATIONAL PSORIASIS FOUNDATION

http://www.psoriasis.org/netcommunity/home

ADVOCACY

Psoriasis Action Network

Walk to Cure Psoriasis

Minimize

The National Psoriasis Foundation Walk to Cure Psoriasis is a nationwide program designed to generate awareness about psoriasis and psoriatic arthritis and raise money for the National Psoriasis Foundation for education, advocacy, and research programs. In just 2 years, the NPF has raised over $1.3 million for research projects, and over 6500 walkers and volunteers have been involved!

We encourage your local DIG Chapter to form a team and participate in a walk near you. Alternatively, if you are interested in volunteering at one of the walks, please contact John Zade at jzade14@gmail.com, and he can put you in touch with the appropriate Walk Coordinator in your area. This is a fun way to support a great cause!

Psoriasis Information

Minimize

WHAT IS PSORIASIS?

Psoriasis is a chronic disease of the immune system that appears on the skin, usually in the form of thick, red, scaly patches. Up to 30 percent of people with psoriasis also develop psoriatic arthritis. Psoriasis is associated with other serious conditions, such as diabetes, heart disease, and obesity. According to the National Institutes of Health, as many as 7.5 million Americans have psoriasis.

There are five types of psoriasis: plaque, guttate, inverse, pustular, erytherodermic. The most common form, plaque psoriasis, appears as raised, red patches or lesions covered with a silvery white buildup of dead skin cells, called scale. Psoriasis can occur on any part of the body and as stated above, is associated with other serious health conditions, including depression, diabetes, and heart disease.


 


Plaque Psoriasis


Guttate Psoriasis

Inverse Psoriasis

Pustular Psoriasis

Erythrodermic Psoriasis

 

 




 

 

Pictures courtesy of National Psoriasis Foundation


WHAT CAUSES PSORIASIS?

The exact cause of psoriasis is unknown. However, it is understood that the immune system and genetics play major roles in its development. Most researchers agree that the immune system is somehow mistakenly triggered, which cause a series of events, including acceleration of skin cell growth. A normal skin cell matures and falls off the body in 28 to 30 days. A skin cell in a patient with psoriasis takes only 3 to 4 days to mature and instead of falling off (shedding), the cells pile up on the surface of the skin, forming psoriasis lesions.

Scientists believe that at least 10 percent of the general population inherits one or more of the genes that create a predisposition to psoriasis. However, only 2 to 3 percent of the population develops the disease. Researchers believe that for a person to develop psoriasis, the individual must have a combination of the genes that cause psoriasis and be exposed to specific external factors, known as "triggers".

Psoriasis Advocacy

Minimize

 

Overcoming obstacles for psoriasis patients: updates on National Psoriasis Foundation legislative efforts.

By Meg Hession, MS4

 

As medical students, we are all familiar with the hallmark erythematous, scaling, pruritic lesions of psoriasis, as taught to us in second year lectures or USMLE study guides. What these books don’t teach us, however, is the less tangible—but no less significant—effects that psoriasis can have on the mental well-being and self-image of patients affected by the disease. Furthermore, psoriasis is associated with a number of other medical conditions.  For example, up to 30% of patients with psoriasis will develop the aching, stiff joints of psoriatic arthritis.  Moreover, new research has shown that psoriasis is associated with a number of other chronic medical conditions, including diabetes, obesity, hypertension, cardiovascular disease, liver disease and Crohn’s disease.   Each year, Americans suffering from this condition lose roughly 56 million hours of work, accounting for approximately 40% of the estimated $11.25 billion in health care costs of psoriasis annually.

Despite the emotional, physical and financial burden imposed by psoriasis, the federal government currently spends a mere $1.38 per patient annually on psoriasis research.  Furthermore, access to care represents a significant barrier for patients and providers, as high copayments and restrictive plans limit treatment options for patients. For example, insurance companies often ration care by requiring symptoms to be present for a certain amount of time before they will cover treatment. Other companies impose restrictions by limiting the amount of time they will cover a particular drug--for example 6 months--even though the nature of psoriasis is that it is a chronic, often lifelong disease. Furthermore, many policies have instituted a system of “step therapy,” whereby patients must first undergo a series of trials on other medications for a specified time interval--often ones that have already failed to work in the past--before they approve use of the originally prescribed treatment.    This is a common scenario for patients with very severe disease, who seek the slightly more expensive--yet more effective--biologic agents such as Humira or Enbrel.   Indeed, these biologic agents are often defined by insurance companies as a “specialty tier four” drug--a higher formulary category which requires higher payments.   

The issue of copayments is also particularly worrisome for patients seeking phototherapy. For example, a 2008 National Psoriasis Foundation survey of nearly 200 dermatologists found that the most common reason among patients for discontinuing light therapy was the cost.  With co-payments of up to $50 per visit (the therapy typically requires three visits per week), patients simply cannot afford their treatment.

 

In light of these disturbing obstacles, efforts are underway by the National Psoriasis Foundation to overhaul such bureaucratic hurdles in order to achieve the goal of improved disease management and symptomatic relief for patients suffering from psoriasis.   Already, the NRF has sent letters to insurance commissioners in California, Massachusetts, Missouri, New York, Texas and Utah asking for their help in convincing insurance companies to remove many of their restrictions.  Furthermore, this access to care initiative is linked to the even larger Psoriasis and Psoriatic Arthritis Research, Cure and Care Act (PPARCCA) of 2009.  This bill, originally drafted in 2007 was re-introduced in the House of Representatives by Rep. David Wu (D-Oregon) in February, 2009 and in the Senate by Robert Menendez (D-New Jersey) in March, 2009. The bill calls for four specific objectives:  first, the expansion of NIH-funded research on psoriasis; second, the development of a national patient registry via the Center for Disease Control; third, the establishment of an annual summit to discuss current aspects of research and patient care.  The fourth and final objective of the bill calls for the Institute of Medicine to evaluate access to care for psoriasis patients and make recommendations for improvement. 

 

Specifically, the National Psoriasis Foundation also called for a $1.5 million appropriation in 2010 to support the development of the CDC-based national patient registry. After months of lobbying on behalf of this bill, the efforts of psoriasis advocates were brought to fruition on July 17, 2009, when the U.S. House of Representatives approved this $1.5 million funding request.   Information gathered from this registry will help researchers further understand the epidemiology of psoriasis and its association with other diseases.   In order for this funding to take effect, the Senate must also approve its version of the bill and an agreement must be reached among House and Senate representatives as to the final appropriation for the fiscal year 2010.  And finally, the bill must be approved by the President.

 

So how can you help?


Further advocacy efforts are needed to propel Congress into its final approval of these appropriations, and to garner further support in the House and Senate for the PPARCCA. The simple act of calling your Congressional office or writing an email can go a long way. 

 

To find out whether representatives in your State support the bill visit:

http://capwiz.com/psoriasis/issues/bills

 

Join the Psoriasis Action Network to find out ways you can help in your area.  Register at:

http://www.psoriasis.org/netcommunity/advocacy_pan_join


REFERENCES 

 

“Congress Takes on Nation’s Most Prevalent Autoimmune Disease.” National Psoriasis Foundation. March 11, 2009. Accessed August 18, 2009. http://www.psoriasis.org/netcommunity/Page.aspx?pid=481

 

“High Copayments Limit Treatment Options for Psoriasis Patients.” National Psoriasis Foundation. January 14, 2009. Accessed August 18, 2009.

http://www.psoriasis.org/netcommunity/Page.aspx?pid=484

 

National Psoriasis Foundation. Access to Care Issue Brief. February 2009. Accessed August 18, 2009. http://www.psoriasis.org/NetCommunity/Document.Doc?id=344

  • http://www.derminterest.org/css/guccioutlet.asp